Bayer CropScience: ₹62 EPS, 45x P/E – Seeds of Growth or Just Weeds?
At a Glance
Bayer CropScience (Bayer’s Indian arm) posted a solid Q1 FY26 with ₹1,915 Cr revenue (+17% YoY) and ₹279 Cr PAT (+9.6% YoY). EPS landed at ₹62, with margins improving to 18%. Yet, the stock tanked 4.5% because investors wanted a miracle harvest, not just steady crops. Dividend? A fat 87% payout—because why not distribute when growth is sluggish?
Introduction
Bayer CropScience is like that nerdy kid who always gets 90% but never 100%. Excellent fundamentals, world-class parentage, strong product portfolio—but the growth curve? About as exciting as watching fertilizer dry. Investors love its dividends, but the premium valuation (45x P/E) screams: “Pay up for safety.”
Business Model (WTF Do They Even Do?)
Core Business: Manufacturing and selling insecticides, fungicides, herbicides, and hybrid corn seeds.
Revenue Drivers: Agrochemical sales, new product launches, and corn seed portfolio.
Other Segments: Technology tie-ups, farmer advisory, and distribution network across rural India.
Roast: They basically sell farmers potions with fancy German names to keep pests away – and charge premium prices while at it.
Financials Overview
Source table
₹ Cr
FY23
FY24
FY25
TTM
Revenue
5,140
5,106
5,473
5,756
EBITDA
924
959
691
723
EBITDA %
18%
19%
13%
13%
PAT
758
740
568
592
Comment: FY25 was a washout with margins sliding, but Q1 FY26 hints at recovery.
Valuation
P/E: 45.5x – rich for a company with single-digit growth.
EV/EBITDA: Also high, thanks to premium brand positioning.
